IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David Robert Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019

Cited by 146 works. doi:10.1093/annonc/mdz293

Authors